Stay updated with breaking news from Biodesix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biodesix, Inc. (NASDAQ:BDSX – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 256,100 shares, a decline of 19.2% from the April 30th total of 317,000 shares. Based on an average daily trading volume, of 84,200 shares, the short-interest ratio is […]
Biodesix, Inc. (NASDAQ:BDSX – Get Rating) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 256,100 shares, a decline of 19.2% from the April 30th total of 317,000 shares. Based on an average daily trading volume, of 84,200 shares, the days-to-cover ratio is currently 3.0 days. […]
Biodesix, Inc. , a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR conference, providing... | May 25, 2023
18.05.2023 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in ... Seite 1
Biodesix, Inc. (NASDAQ:BDSX – Get Rating) CEO Scott Hutton sold 9,934 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $1.57, for a total value of $15,596.38. Following the completion of the sale, the chief executive officer now owns 244,570 shares of the company’s […]